FUNDC2 Inhibitors

FUNDC2 inhibitors belong to a distinctive chemical class renowned for their role in modulating cellular processes related to mitophagy, a critical mechanism for maintaining mitochondrial homeostasis. Fundamentally, FUNDC2 (Fun14 domain-containing protein 2) serves as a key regulator in the initiation of mitophagy, a selective autophagic process that ensures the removal of damaged or dysfunctional mitochondria. This protein, predominantly located on the outer mitochondrial membrane, interacts with other proteins and components of the autophagy machinery to orchestrate the engulfment and subsequent degradation of impaired mitochondria. Inhibitors targeting FUNDC2 aim to fine-tune this cellular process by impeding the interactions or molecular events necessary for the activation of FUNDC2-mediated mitophagy. FUNDC2 inhibitors are characterized by their ability to interfere with the binding sites or molecular interfaces crucial for FUNDC2's engagement with downstream effectors. This interference, achieved through various molecular mechanisms, ultimately disrupts the intricate signaling cascade that leads to the initiation of mitophagy. As a consequence, the inhibition of FUNDC2 hinders the timely removal of damaged mitochondria, potentially influencing cellular health and metabolic regulation. Researchers exploring the pharmacological properties of FUNDC2 inhibitors aim to elucidate their specific modes of action and potential implications in cellular physiology, offering valuable insights into the intricate molecular mechanisms governing mitophagy and its broader impact on cellular homeostasis.